Delivering precision oncology to patients with cancer

被引:218
作者
Mateo, Joaquin [1 ,2 ]
Steuten, Lotte [3 ,4 ]
Aftimos, Philippe [5 ]
Andre, Fabrice [6 ]
Davies, Mark [7 ]
Garralda, Elena [1 ,2 ]
Geissler, Jan [8 ]
Husereau, Don [9 ]
Martinez-Lopez, Iciar [10 ]
Normanno, Nicola [11 ]
Reis-Filho, Jorge S. [12 ]
Stefani, Stephen [13 ]
Thomas, David M. [14 ]
Westphalen, C. Benedikt [15 ,16 ,17 ]
Voest, Emile [18 ,19 ]
机构
[1] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[2] Vall dHebron Univ Hosp, Barcelona, Spain
[3] Off Hlth Econ, London, England
[4] City Univ London, London, England
[5] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium
[6] Univ Paris Saclay, INSERM U981, Inst Gustave Roussy, Villejuif, France
[7] South Wales West Canc Ctr, Swansea, W Glam, Wales
[8] Patvocates, Munich, Germany
[9] Univ Ottawa, Ottawa, ON, Canada
[10] Son Espases Univ Hosp, Unit Genet & Genom Balearic Isl, Illes, Balears, Spain
[11] Ist Nazl Tumori IRCCS Fdn G Pascale, Cell Biol & Biotherapy Unit, Naples, Italy
[12] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[13] UNIMED RS, Porto Alegre, RS, Brazil
[14] Garvan Inst Med Res, Sydney, NSW, Australia
[15] Ludwig Maximilian Univ Munich, Comprehens Canc Ctr Munich, Munich, Germany
[16] Ludwig Maximilian Univ Munich, Dept Med 3, Munich, Germany
[17] German Canc Consortium DKTK Partner Site Munich, Heidelberg, Germany
[18] Netherlands Canc Inst, Amsterdam, Netherlands
[19] Oncode Inst, Utrecht, Netherlands
关键词
REAL-WORLD EVIDENCE; CELL LUNG-CANCER; MEDICINE; FRAMEWORK; VARIANTS;
D O I
10.1038/s41591-022-01717-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Precision medicine is reshaping cancer care, but the benefits are not accessible to all patients. This Perspective outlines the major challenges to the implementation of precision oncology and discusses critical steps toward resolving these. With the increasing use of genomic profiling for diagnosis and therapy guidance in many tumor types, precision oncology is rapidly reshaping cancer care. However, the current trajectory of drug development in oncology results in a paradox: if patients cannot access advanced diagnostics, we may be developing drugs that will reach few patients. In this Perspective, we outline the major challenges to the implementation of precision oncology and discuss critical steps toward resolving these, including facilitation of equal access to genomics tests, ensuring that clinical studies provide robust evidence for new drugs and technologies, enabling physicians to interpret genomics data, and empowering patients toward shared decision-making. A multi-stakeholder approach to evidence generation, value assessment, and healthcare delivery is necessary to translate advances in precision oncology into benefits for patients with cancer globally.
引用
收藏
页码:658 / 665
页数:8
相关论文
共 68 条
[1]   From Tissue-Agnostic to N-of-One Therapies:(R)Evolution of the Precision Paradigm [J].
Adashek, Jacob J. ;
Subbiah, Vivek ;
Kurzrock, Razelle .
TRENDS IN CANCER, 2021, 7 (01) :15-28
[2]  
All of Us Research Hub, 2024, How Does All of Us Assess Diversity? What Communities Does All of Us Consider Underrepresented in Biomedical Research (UBR)? All of Us Research Hub
[3]   Real-world data: towards achieving the achievable in cancer care [J].
Booth, Christopher M. ;
Karim, Safiya ;
Mackillop, William J. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (05) :312-325
[4]   Enabling Precision Oncology Through Precision Diagnostics [J].
Brown, Noah A. ;
Elenitoba-Johnson, Kojo S. J. .
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 15, 2020, 2020, 15 :97-121
[5]   Real-World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe [J].
Cave, Alison ;
Kurz, Xavier ;
Arlett, Peter .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 106 (01) :36-39
[6]  
Chakravarty D, 2017, JCO PRECIS ONCOL, V1
[7]   Estimated Cost of Anticancer Therapy Directed by Comprehensive Genomic Profiling in a Single-Center Study [J].
Chawla, Anita ;
Janku, Filip ;
Wheler, Jennifer J. ;
Miller, Vincent A. ;
Ryan, Jason ;
Anhorn, Rachel ;
Zhou, Zhou ;
Signorovitch, James .
JCO PRECISION ONCOLOGY, 2018, 2 :1-11
[8]   Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) [J].
Condorelli, R. ;
Mosele, F. ;
Verret, B. ;
Bachelot, T. ;
Bedard, P. L. ;
Cortes, J. ;
Hyman, D. M. ;
Juric, D. ;
Krop, I. ;
Bieche, I. ;
Saura, C. ;
Sotiriou, C. ;
Cardoso, F. ;
Loibl, S. ;
Andre, F. ;
Turner, N. C. .
ANNALS OF ONCOLOGY, 2019, 30 (03) :365-373
[9]   Oncologist Confidence in Genomic Testing and Implications for Using Multimarker Tumor Panel Tests in Practice [J].
de Moor, Janet S. ;
Gray, Stacy W. ;
Mitchell, Sandra A. ;
Klabunde, Carrie N. ;
Freedman, Andrew N. .
JCO PRECISION ONCOLOGY, 2020, 4 :620-631
[10]   Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions [J].
Deverka, Patricia A. ;
Douglas, Michael P. ;
Phillips, Kathryn A. .
VALUE IN HEALTH, 2020, 23 (05) :540-550